BioSpace News Archive

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Cervical Spine Research Society (CSRS) as a diamond sponsor and will attend the CSRS 50th Annual Meeting held November 16 to 19 in San Diego.

UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its investigational treatment, zilucoplan.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the third quarter of 2022.

Stoke Therapeutics, Inc. today reported financial results for the third quarter of 2022 and provided business updates, including positive data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome.

Kezar Life Sciences, Inc. today announced that it presented the complete data set from the MISSION Phase 2 clinical trial evaluating zetomipzomib in active lupus nephritis (LN) at the American College of Rheumatology (ACR) Convergence 2022 in Philadelphia, PA.

Akouos, Inc. today reports financial results for the third quarter ended September 30, 2022 and provides business highlights.

Virios Therapeutics, Inc. today announced financial results for the third quarter ended September 30, 2022, as well as plans to advance development of its lead antiviral development candidate, IMC-1, as a potential new treatment for FM patients.

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous dosing regimen of the G3 formulation of luxeptinib, a potent, non-covalent oral inhibitor of BTK and FLT3, in the ongoing Phase 1a/b clinical trial in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML).

Gelesis Holdings today reported financial results for the third quarter of 2022.

Windtree Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided key business updates.